National Institute for Health and Care Excellence

In consultation: Guidance and quality standards

Brentuximab vedotin with etoposide, cyclophosphamide, doxorubicin, dacarbazine and dexamethasone for untreated advanced classical Hodgkin lymphoma ID6437 Consultation on suggested remit, draft scope ...
The National Institute for Health and Care Excellence

Patients to get new medicines up to six months sooner

As a practising surgeon, I know how important it is that patients get access to the latest treatments as quickly as possible. That’s why we’re cutting red tape so safe and effective new medicines can ...
National Institute for Health and Care Excellence

Suspected sepsis: recognition, diagnosis and early management

This guideline has been updated and replaced by NICE's guidelines on suspected sepsis in people aged 16 or over (NG253), suspected sepsis in under 16s (NG254) and suspected sepsis in pregnant or ...
The National Institute for Health and Care Excellence

500,000 eligible to benefit from new non-hormonal treatment for hot flushes caused by menopause

A new treatment option for menopausal hot flushes and night sweats can be used in the NHS when hormone replacement therapy ...
The National Institute for Health and Care Excellence

Saving babies' hearing: how a world-first rapid genetic test is transforming neonatal care

Learn how NICE's healthtech guidance helped bring life-changing genetic testing to neonatal units across the UK, saving 20 ...
National Institute for Health and Care Excellence

Baloxavir marboxil for treating and preventing influenza in children 1 to 11 years (terminated appraisal)

NICE is unable to make a recommendation on baloxavir marboxil (Xofluza) for treating and preventing influenza in children 1 to 11 years. This is because the company did not provide an evidence ...